Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Monday: Facebook Inc (NASDAQ:FB), Cisco Systems, Inc (NASDAQ:CSCO), Ford Motor Company (NYSE:F), Pfizer Inc (NYSE:PFE)
- Facebook Inc (NASDAQ:FB), with shares dwindled-0.32% is now trading at $77.77. The Stock is active as 6.89M shares changed hands versus its average volume of 24.51M shares.
- Cisco Systems, Inc (NASDAQ:CSCO), with shares raised 0.68% is now trading at $28.13. The Stock is active as 6.73M shares changed hands versus its average volume of 31.15M shares.
- Ford Motor Company (NYSE:F) with shares enhanced 0.86% is now trading at $16.34. The Stock is active as 6.43M shares changed hands versus its average volume of 27.14M shares.
- Pfizer Inc (NYSE:PFE), with shares rose 1.47% is now trading at $34.50. The Stock is active as 6.06M shares changed hands versus its average volume of 30.93M shares.
Latest NEWS regarding these Stocks are depicted underneath:
Facebook, Inc. (NASDAQ:FB)
On Monday morning, the analysts at Bank of America/Merrill Lynch, provides a positive note on its purchase of photo-sharing app Instagram.
The firm maintained its “buy” rating with a $92 price target on shares of the social media giant, and said that its purchase of Instagram is proving to be a steal. BofA/Merrill Lynch analysts noted that Instagram has exceeded the firm’s user expectations.
Facebook, Inc. operates as a social networking corporation worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Cisco Systems, Inc. (NASDAQ:CSCO)
Today, Cisco Systems, Inc. (CSCO)’s collaboration SVP Rowan Trollope to “Reimagine Collaboration” in Streamed Keynote at Enterprise Connect on March 17. Trollope to Unveil innovations that are modernizing partnership in every room, on every desk and in every pocket.
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking products and services related to the communications and information technology industry worldwide.
Ford Motor Co. (NYSE:F)
On March 13, Ford Motor Co. (F), marked the official start of production of the all-new 2015 F-150 at Kansas City Assembly Plant, which joins Dearborn Truck Plant in building the toughest, smartest, most capable F-150 ever.
This means Ford has expanded production of the first mass-produced light-duty pickup truck with a high-strength, military-grade, aluminum-alloy body. In addition to producing all F-150 models and cab configurations, production at Kansas City Assembly Plant now comprises F-150s with an 8-foot cargo box and heavy payload package to meet the needs of commercial fleet customers.
The all-new F-150 is off to a strong start. In January, F-Series had its strongest sales month since 2004 – Ford’s best sales year ever for F-150. Retail sales raised 7 percent in February. These numbers make F-Series one of Ford’s fastest-selling vehicles, at just 18 days to turn on dealer lots – well below the light-duty full-size pickup truck average of 105 days.
F-150 is part of the Ford F-Series lineup. Now in its 67th year, F-Series has been the best-selling vehicle in America for 33 successive years and America’s favorite truck for 38 years.
Ford Motor Corporation, a global automotive industry leader based in Dearborn, Michigan, manufactures or distributes automobiles across six continents. With about 187,000 employees and 62 plants worldwide, the corporation’s automotive brands comprise Ford and Lincoln.
Pfizer Inc. (NYSE:PFE)
On March 12, Pfizer Inc. (PFE), declared top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM). The primary endpoint of the study was not achieved as there was not a statistically noteworthy difference between pregabalin and placebo in mean pain score. The treatment difference was 0.66 points, which reflects an improvement of 1.60 points from baseline for pregabalin-treated patients and 0.94 points for placebo (p=0.121). This study was conducted to fulfill a post-marketing commitment required by the U.S. Food and Drug Administration (FDA) when Lyrica was approved for the administration of fibromyalgia. The safety and efficacy of pregabalin in pediatric patients have not been established.
A total of 107 adolescent patients were enrolled in this Phase 4, 15-week double-blind, randomized, placebo-controlled study from multiple centers across the U.S., Europe and Asia. This study is the first large pharmacological treatment study to be accomplished in this study population.
Study medication was administered twice daily. Dosing started at 75 mg/day and was optimized over a 3 week period, based on tolerability and response, to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day, with the optimized dose maintained for the next 12 weeks.
The safety profile observed in this study is consistent with the known profile for Lyrica in preceding fibromyalgia studies in adults, with the exception of mild nausea, which occurred at a higher rate in pregabalin-treated patients. The most ordinary adverse events in this study in pregabalin treated patients were dizziness, nausea, headache, raised weight and fatigue.
Full results from the study are predictable to be presented for publication when analyses are complete.
Pfizer Inc., a biopharmaceutical corporation, discovers, develops, manufactures, and sells healthcare products worldwide. The corporation operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
